MKC 121

Drug Profile

MKC 121

Latest Information Update: 07 Jun 2001

Price : $50

At a glance

  • Originator Mitsubishi Chemical
  • Class Antihyperlipidaemics
  • Mechanism of Action Sterol O-acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 07 Jun 2001 Discontinued-I for Hyperlipidaemia in Japan (Unknown route)
  • 01 Nov 1998 No-Development-Reported for Hyperlipidaemia in Japan (Unknown route)
  • 01 Aug 1996 Phase-I clinical trials for Hyperlipidaemia in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top